Search

Your search keyword '"Thomas Kielsgaard Kristensen"' showing total 68 results

Search Constraints

Start Over You searched for: Author "Thomas Kielsgaard Kristensen" Remove constraint Author: "Thomas Kielsgaard Kristensen" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
68 results on '"Thomas Kielsgaard Kristensen"'

Search Results

1. Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options (PRECODE): study protocol of a prospective, non-randomized, cohort study

2. Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)

4. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

5. Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC

6. Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses

7. IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load

8. A retrospective cohort study of patients with eosinophilia referred to a tertiary centre

9. Impaired immune responses to herpesviruses and microbial ligands in patients with Mono <scp>MAC</scp>

10. Adverse prognostic impact of the kit d816v transcriptional activity in advanced systemic mastocytosis

11. Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure

12. Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis

13. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations

14. Comparison of RNA-Based Versus DNA-Based Quantitative KIT D816V Mutation Analysis Reveals Significant Disparity in Patients with Advanced Systemic Mastocytosis

15. International external quality assurance of JAK2 V617F quantification

16. Sensitive quantification of the intronless SOX11 mRNA from lymph nodes biopsies in mantle cell lymphoma

17. Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma

18. Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population-based study

19. Erratum to 'Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma' [Experimental Hematology 84 (2020) 7–18]

20. Towards rational diagnostics in mastocytosis:clinical validation of sensitive KIT D816V mutation analysis of unfractionated whole-blood

21. Detection of free intraperitoneal tumour cells in peritoneal lavage fluid from patients with peritoneal metastasis before and after treatment with pressurised intraperitoneal aerosol chemotherapy (PIPAC)

22. Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

23. Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit)

24. Chronic lymphocytic leukemia patients with heterogeneously or fully methylated LPL promotor display longer time to treatment

25. Pediatric Expression of Mast Cell Activation Disorders

26. NEW POTENTIAL CANDIDATE GENES IN MANTLE CELL LYMPHOMA

27. Targeted ultradeep next-generation sequencing as a method forKITD816V mutation analysis in mastocytosis

28. KIT mutation analysis in mast cell neoplasms

29. Comparison of gDNA-based versus mRNA-based KIT D816V mutation analysis reveals large differences between blood and bone marrow in systemic mastocytosis

30. A child with mastocytosis and lymphomatoid papulosis

31. Patterns of anaphylaxis after diagnostic workup:A follow-up study of 226 patients with suspected anaphylaxis

32. Venom anaphylaxis can mimic other serious conditions and disclose important underlying disease

33. Fatal anaphylaxis following a hornet sting in a yellow jacket venom-sensitized patient with undetected monoclonal mast cell activation syndrome and without previous history of a systemic sting reaction

34. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis

35. SensitiveKITD816V mutation analysis of blood as a diagnostic test in mastocytosis

36. Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

37. KIT D816V Mutation-Positive Cell Fractions in Lesional Skin Biopsies from Adults with Systemic Mastocytosis

38. LPL gene expression is associated with poor prognosis in CLL and closely related to NOTCH1 mutations

39. Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population-based study

40. The effect of fines on nonattendance in public hospital outpatient clinics: study protocol for a randomized controlled trial

41. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia

42. [Mastocytosis]

43. NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression*

44. Seminal human papillomavirus originates from the body surface and is not a frequent aetiological factor in azoospermia

45. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; The American Academy of Allergy, Asthma & Immunology; And the European Academy of Allergology and Clinical Immunology

46. Multidisciplinary Management of Mastocytosis: Nordic Expert Group Consensus

47. [New disease markers within the chronic myeloproliferative neoplasms]

48. Adult-onset systemic mastocytosis in monozygotic twins with KIT D816V and JAK2 V617F mutations

49. No Development of Neutralizing Antibodies Against Recombinant Interferon-Alpha in Ph-Negative Myeloproliferative Neoplasms:a Prospective Study

50. Recognizing mastocytosis in patients with anaphylaxis: Value of KIT D816V mutation analysis of peripheral blood

Catalog

Books, media, physical & digital resources